7 completed, 4 active not recruiting, 4 recruiting, 4 terminated. 12 Phase 2, 6 Phase 1, 5 Not applicable.
Follow Gallbladder Carcinoma: new trials by email Literature Review of Gallbladder Carcinoma trials Research Report on Gallbladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-11-10 |
| Outcomes After Liver and Biliary Resection at a High-Volume Center Liver Neoplasms, Hepatobiliary Diseases | Not yet recruiting | Azienda USL Toscana Centro | 1000 | 2026-04-01 | 2026-04-29 | |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| Target-specific immunoPET Imaging of Digestive System Carcinoma [68Ga]Ga-DOTA-H2D3, [18F]F-RESCA-RB14, [68Ga]Ga-NOTA-T4 - Malignancy, Digestive Cancer | Not applicable | Recruiting | RenJi Hospital | 400 | 2024-12-04 | 2025-12-31 |
| Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards ADBoard - Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma | Not applicable | Unknown | Charite University, Berlin, Germany | 1200 | 2023-11-01 | 2023-08-24 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases Cisplatin, Gemcitabine, Nab-paclitaxel - Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-09-19 | 2026-08-03 |
| Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device CATUVAB - Bladder Carcinoma, Prostate Tumor | Not applicable | Completed | Lindis Bloodcare GmbH | 136 | 2022-02-15 | 2025-01-23 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Felmetatug Vedotin, Pembrolizumab - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 250 | 2022-01-12 | 2026-01-09 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors ELI-002 2P - Minimal Residual Disease, KRAS G12D | Phase 1 | Completed | Elicio Therapeutics | 25 | 2021-10-04 | 2025-09-05 |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Irinotecan Liposome Injection, SG001, Fluorouracil - Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | CSPC Ouyi Pharmaceutical Co., Ltd. | 17 | 2021-09-01 | 2024-07-11 |
| A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP Endoscopic Retrograde Cholangiopancreatography - Bile Duct Carcinoma, Gallbladder Carcinoma | Not applicable | Completed | M.D. Anderson Cancer Center | 66 | 2021-02-24 | 2024-11-06 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers tucatinib, trastuzumab, oxaliplatin - Colorectal Carcinoma, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 40 | 2020-09-15 | 2026-02-24 |
| Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA gemcitabine and oxaliplatin., Afatinib - Gallbladder Carcinoma | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 102 | 2020-06-01 | 2024-10-16 |
| Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma Apatinib, Tegafur - Gallbladder Carcinoma | Phase 2 | Unknown | Eastern Hepatobiliary Surgery Hospital | 138 | 2018-08-10 | 2018-10-11 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
| A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients Proteinosis, Gallbladder Carcinoma | Unknown | liu yingbin | 50 | 2018-01-01 | 2018-07-10 | |
| Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma" Gallbladder Carcinoma | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 200 | 2017-10-11 | 2024-03-06 | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
Showing 20 of 26. Sign in to see all of them.
Gallbladder Neoplasms (26) · Cholangiocarcinoma (16) · Bile Duct Neoplasms (6) · Carcinoma, Hepatocellular (5) · Stomach Neoplasms (5) · Colonic Neoplasms (4) · Gastrointestinal Neoplasms (4) · Pancreatic Neoplasms (4) · Biliary Tract Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Esophageal Neoplasms (3) · Liver Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Adenoid Cystic (2) · Colorectal Neoplasms (2)
Gallbladder Diseases (26) · Neoplasms by Site (26) · Biliary Tract Diseases (25) · Digestive System Diseases (25) · Digestive System Neoplasms (25) · Neoplasms (25) · Biliary Tract Neoplasms (23) · Adenocarcinoma (18) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (18) · Carcinoma (17) · Gastrointestinal Diseases (8) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Liver Diseases (7)
Gemcitabine (6) · Oxaliplatin (6) · Fluorouracil (4) · Leucovorin (4) · Cisplatin (3) · Albumin-Bound Paclitaxel (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Taxes (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · AZD 6244 (1) · Afatinib (1) · Biopsy (1)
National Cancer Institute (NCI) (2) · Seagen, a wholly owned subsidiary of Pfizer (2) · University Health Network, Toronto (2) · Azienda USL Toscana Centro (1) · Beijing Biotech (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Case Comprehensive Cancer Center (1) · Charite University, Berlin, Germany (1) · City of Hope Medical Center (1) · Eastern Hepatobiliary Surgery Hospital (1) · Elicio Therapeutics (1) · Hellenic Cooperative Oncology Group (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Lindis Bloodcare GmbH (1) · Lisata Therapeutics, Inc. (1)
United States (12) · China (7) · Germany (4) · Canada (2) · Greece (1) · Guam (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Jennifer Knox, M.D. (2) · Chi Cao, MD (1) · Daneng Li, MD (1) · Felix Krenzien (1) · Haruka Itakura (1) · Joseph Sgouros, MD (1) · Katherine Hagan (1) · Kristen K Buck, MD (1) · Madison Conces, MD (1) · Manish Sharma (1) · Markus Heiss, MD (1) · Massimo Fedi, MD (1) · Mustafa Raoof, MD (1) · Nilo Azad, MD (1)
PMID 30968181, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 34907910, PMID 36854604, PMID 37684688, PMID 38195752, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39263892, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 40790272, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
2023 (2), P30CA014599 (1), P30CA033572 (1), U10CA180888 (1), UM1CA186691 (1)